Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review

Passero L, Simon TA, Zhong Y, Zhuo J, Varga S, Armstrong AW. Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic[...]

Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination

Wang J, Patel S, Kolker S, Bennett RG. Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination. Dermatol Surg. 2025 Dec[...]

Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis

Yan MJ, Jiang YC, Wongvibulsin S, Chen ST. Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis. JID Innov. 2025 Nov 17;6(2):100435.[...]